Beta2-Adrenoceptor Stimulation Suppresses TLR9-Dependent IFNA1 Secretion in Human Peripheral Blood Mononuclear Cells

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Hilbert, Tobias ^a   Bongartz, Josef ^a   Weisheit, Christina ^a   Knüfermann, Pascal ^a   Baumgarten, Georg ^a   Hoeft, Andreas ^a   Poth, Jens M ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ALPHA1 INTERFERON; BETA 2 ADRENERGIC RECEPTOR; TOLL LIKE RECEPTOR 9; ALPHA INTERFERON; IFNA1 PROTEIN, HUMAN; TLR4 PROTEIN, HUMAN; TLR9 PROTEIN, HUMAN; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ADRENERGIC STIMULATION; ARTICLE; BLOOD BUFFY COAT; CELL VIABILITY; COLORIMETRY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMACYTOID DENDRITIC CELL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; BYSTANDER EFFECT; CELL COMMUNICATION; CYTOLOGY; DENDRITIC CELL; METABOLISM; MONONUCLEAR CELL; SECRETION (PROCESS);

BYSTANDER EFFECT; CELL COMMUNICATION; DENDRITIC CELLS; HUMANS; INTERFERON-ALPHA; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; RECEPTORS, ADRENERGIC, BETA-2; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84878386052     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065024     Document Type: Article

References (39)

1. Lande R, Gilliet M, (2010) Plasmacytoid dendritic cells: key players in the initiation and regulation of immune responses. Ann N Y Acad Sci 1183: 89-103.
2. Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, et al. (1999) The nature of the principal type 1 interferon-producing cells in human blood. Science 284: 1835-1837.
3. Poth JM, Coch C, Busch N, Boehm O, Schlee M, et al. (2010) Monocyte-mediated inhibition of TLR9-dependent IFN-alpha induction in plasmacytoid dendritic cells questions bacterial DNA as the active ingredient of bacterial lysates. J Immunol 185: 7367-7373.
4. Colonna M, Trinchieri G, Liu YJ, (2004) Plasmacytoid dendritic cells in immunity. Nat Immunol 5: 1219-1226.
5. Poeck H, Wagner M, Battiany J, Rothenfusser S, Wellisch D, et al. (2004) Plasmacytoid dendritic cells, antigen, and CpG-C license human B cells for plasma cell differentiation and immunoglobulin production in the absence of T-cell help. Blood 103: 3058-3064.
6. Ablasser A, Poeck H, Anz D, Berger M, Schlee M, et al. (2009) Selection of molecular structure and delivery of RNA oligonucleotides to activate TLR7 versus TLR8 and to induce high amounts of IL-12p70 in primary human monocytes. J Immunol 182: 6824-6833.
7. Liu C, Lou Y, Lizee G, Qin H, Liu S, et al. (2008) Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J Clin Invest 118: 1165-1175.
8. Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, et al. (2005) Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 11: 263-270.
9. Janke M, Poth J, Wimmenauer V, Giese T, Coch C, et al. (2009) Selective and direct activation of human neutrophils but not eosinophils by Toll-like receptor 8. J Allergy Clin Immunol 123: 1026-1033.
10. Coch C, Busch N, Wimmenauer V, Hartmann E, Janke M, et al. (2009) Higher activation of TLR9 in plasmacytoid dendritic cells by microbial DNA compared with self-DNA based on CpG-specific recognition of phosphodiester DNA. J Leukoc Biol 86: 663-670.
11. Krieg AM, (2006) Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 5: 471-484.
12. Krieg AM, Vollmer J, (2007) Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity. Immunol Rev 220: 251-269.
13. Honda K, Ohba Y, Yanai H, Negishi H, Mizutani T, et al. (2005) Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction. Nature 434: 1035-1040.
14. Cervantes-Barragan L, Lewis KL, Firner S, Thiel V, Hugues S, et al. (2012) Plasmacytoid dendritic cells control T-cell response to chronic viral infection. Proc Natl Acad Sci U S A 109: 3012-3017.
15. Martinet J, Dufeu-Duchesne T, Bruder Costa J, Larrat S, Marlu A, et al. (2012) Altered functions of plasmacytoid dendritic cells and reduced cytolytic activity of natural killer cells in patients with chronic HBV infection. Gastroenterology 143: 1586-1596 e1588.
16. Florentin J, Aouar B, Dental C, Thumann C, Firaguay G, et al. (2012) HCV glycoprotein E2 is a novel BDCA-2 ligand and acts as an inhibitor of IFN production by plasmacytoid dendritic cells. Blood 120: 4544-4551.
17. Gilliet M, Cao W, Liu YJ, (2008) Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat Rev Immunol 8: 594-606.
18. Lande R, Gregorio J, Facchinetti V, Chatterjee B, Wang YH, et al. (2007) Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 449: 564-569.
19. Pinto A, Rega A, Crother TR, Sorrentino R, (2012) Plasmacytoid dendritic cells and their therapeutic activity in cancer. Oncoimmunology 1: 726-734.
20. Li CY, Chou TC, Lee CH, Tsai CS, Loh SH, et al. (2003) Adrenaline inhibits lipopolysaccharide-induced macrophage inflammatory protein-1 alpha in human monocytes: the role of beta-adrenergic receptors. Anesth Analg 96: 518-523 table of contents.
21. Wahle M, Neumann RP, Moritz F, Krause A, Buttgereit F, et al. (2005) Beta2-adrenergic receptors mediate the differential effects of catecholamines on cytokine production of PBMC. J Interferon Cytokine Res 25: 384-394.
22. Takahashi HK, Iwagaki H, Mori S, Yoshino T, Tanaka N, et al. (2004) Beta 2-adrenergic receptor agonist induces IL-18 production without IL-12 production. J Neuroimmunol 151: 137-147.
23. Flierl MA, Rittirsch D, Nadeau BA, Chen AJ, Sarma JV, et al. (2007) Phagocyte-derived catecholamines enhance acute inflammatory injury. Nature 449: 721-725.
24. Flierl MA, Rittirsch D, Nadeau BA, Sarma JV, Day DE, et al. (2009) Upregulation of phagocyte-derived catecholamines augments the acute inflammatory response. PLoS One 4: e4414.
25. Pross HF, Baines MG, Rubin P, Shragge P, Patterson MS, (1981) Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity. J Clin Immunol 1: 51-63.
26. West WH, Cannon GB, Kay HD, Bonnard GD, Herberman RB, (1977) Natural cytotoxic reactivity of human lymphocytes against a myeloid cell line: characterization of effector cells. J Immunol 118: 355-361.
27. Kizaki T, Izawa T, Sakurai T, Haga S, Taniguchi N, et al. (2008) Beta2-adrenergic receptor regulates Toll-like receptor-4-induced nuclear factor-kappaB activation through beta-arrestin 2. Immunology 124: 348-356.
28. Kizaki T, Shirato K, Sakurai T, Ogasawara JE, Oh-ishi S, et al. (2009) Beta2-adrenergic receptor regulate Toll-like receptor 4-induced late-phase NF-kappaB activation. Mol Immunol 46: 1195-1203.
29. Wang W, Xu M, Zhang YY, He B, (2009) Fenoterol, a beta(2)-adrenoceptor agonist, inhibits LPS-induced membrane-bound CD14, TLR4/CD14 complex, and inflammatory cytokines production through beta-arrestin-2 in THP-1 cell line. Acta Pharmacol Sin 30: 1522-1528.
30. Collado-Hidalgo A, Sung C, Cole S, (2006) Adrenergic inhibition of innate anti-viral response: PKA blockade of Type I interferon gene transcription mediates catecholamine support for HIV-1 replication. Brain Behav Immun 20: 552-563.
31. Berggren O, Hagberg N, Weber G, Alm GV, Ronnblom L, et al. (2012) B lymphocytes enhance interferon-alpha production by plasmacytoid dendritic cells. Arthritis Rheum 64: 3409-3419.
32. Hellstrand K, Hermodsson S, Strannegard O, (1985) Evidence for a beta-adrenoceptor-mediated regulation of human natural killer cells. J Immunol 134: 4095-4099.
33. Krieg AM, (2002) CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20: 709-760.
34. Laurent C, Nobili S, Rullier A, Vendrely V, Saric J, et al. (2006) Efforts to improve local control in rectal cancer compromise survival by the potential morbidity of optimal mesorectal excision. J Am Coll Surg 203: 684-691.
35. Tan HJ, Hafez KS, Ye Z, Wei JT, Miller DC, (2012) Postoperative complications and long-term survival among patients treated surgically for renal cell carcinoma. J Urol 187: 60-66.
36. Takeuchi H, Saikawa Y, Oyama T, Ozawa S, Suda K, et al. (2010) Factors influencing the long-term survival in patients with esophageal cancer who underwent esophagectomy after chemoradiotherapy. World J Surg 34: 277-284.
37. Farid SG, Aldouri A, Morris-Stiff G, Khan AZ, Toogood GJ, et al. (2010) Correlation between postoperative infective complications and long-term outcomes after hepatic resection for colorectal liver metastasis. Ann Surg 251: 91-100.
38. Tsujimoto H, Ichikura T, Ono S, Sugasawa H, Hiraki S, et al. (2009) Impact of postoperative infection on long-term survival after potentially curative resection for gastric cancer. Ann Surg Oncol 16: 311-318.
39. Hotchkiss RS, Karl IE, (2003) The pathophysiology and treatment of sepsis. N Engl J Med 348: 138-150.